Citations

Clear

228 citation(s) found for "SS, Rich".

Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).
Segovia, Diana I. , Sinicrope, Frank A. , Hardin, Aaron , Rich, Thereasa A. , Alberts, Steven R. , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3504-3504

10.1200/jco.2025.43.16_suppl.3504 Get It

3504 Background: Among patients with resected node-positive colon cancer, nearly 30% will relapse despite standard adjuvant chemotherapy. Analysis of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) may enable risk stratification for tumor recurrence and inform adjuvant treatment decisions. Methods: Postsurgical ctDNA was analyzed in patients with stage III colon carcinoma who participated in a phase 3 trial of adjuvant FOLFOX alone or combined with cetuximab (n = 3084) [NCCTG N0147]. We utilized a tissue-free epigenomic assay for ctDNA detection (Guardant Reveal) with sampling prior to start of adjuvant therapy. Among ctDNA positives, epigenomic tumor fraction (TF) was estimated and ctDNA genotyping was done with Guardant360 (panel of 739 genes). Median follow-up was 6.1 years (yr). Study endpoints included time-to-recurrence (TTR), disease-free survival (DFS) and overall survival (OS) analyzed by Kaplan–Meier method. Multivariable Cox proportional hazards models were used to assess prognostic utility of ctDNA status adjusting for confounders. Interaction between ctDNA and clinicopathological features were assessed. Results: Among 2260 patients with evaluable ctDNA data, 461 (20.4%) were ctDNA positive.Tumors were significantly associated with higher T, N stage, BRAF V600E , high grade, obstruction/perforation, and worse performance status. Positive vs negative ctDNA was significantly associated with shorter TTR (hazard ratio [HR] 4.33, 95% confidence interval [CI] 3.65-5.13, P < 0.0001), poorer DFS (HR 3.74, CI 3.18-4.39, P < 0.0001] and OS (HR 3.17, CI 2.63-3.83, P < 0.0001), adjusting for covariates and tissue MMR, KRAS and BRAF V600E . ctDNA positive vs negative patients had 3y DFS of 36.4% (95%CI 32.2-41.2%) vs 82.5% (95% CI 80.0-84.4%), respectively. Adverse prognosis was consistent across subgroups (all P < 0.05), with stronger detrimental effects for positive ctDNA in N1 (vs. N2), T1/2 (vs T3 or 4), and mismatch repair deficient tumors [interaction P = 0.0002 to 0.041). Among patients with positive ctDNA, TF in those who recurred/died within 3 yr was double of those who remained recurrence-free ( P = 0.0001). High vs. low ctDNA TF ( > vs ≤ median) further stratified TTR (HR 1.48, CI 1.17-1.88, P = 0.0011), DFS (HR 1.52, CI 1.21-1.92, P = 0.0004) and OS (HR 1.58, CI 1.21-2.07, P = 0.0009), adjusting for confounders. ctDNA positive cases, . Analyses of ctDNA detection by site of recurrence, ctDNA clearance, and genomic variant detection are ongoing. Conclusions: In the largest study evaluating tissue-free epigenomic-based MRD detection, we demonstrate a robust prognostic utility of postsurgical ctDNA. Tumor fraction provided further patient stratification and analysis is ongoing to identify a subgroup based on TF that may be unlikely to clear ctDNA despite adjuvant chemotherapy.
Contemporary Biology, Management, and Outcomes of Renal Medullary Carcinoma in Children and Adults: A Pediatric Surgical Oncology Research Collaborative Study
Beckhorn, Catherine B , Malek, Marcus M. , Lovvorn, Harold N. , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Hoyt, David , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Marchese, Charles R. , Jensen, Amanda , Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M. , Piché, Nelson , Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Castle, Shannon L. , Mello, Kathryn Bandeira de, Short, Joshua , Petroze, Robin T. , Rajaval, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Newman, Erika A. , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit , Polites, Stephanie F. , Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G. , Barkhordar, Aaron, Austin, Mary T. , Coakley, Brian A. , Kahan, Anastasia M , Murphy, Joseph T., Pitonak, Michael, Boehmer, Chloé , Tracy, Elisabeth T. , Kastenberg, Zachary J , Hoyt, David W , Cost, Nicholas G , Marchese, Charles R , Lautz, Timothy , Lundstedt, John , Brungardt, Joseph G , Talbot, Lindsay J , Murphy, Andrew J , Aldrink, Jennifer H , Piche, Nelson , Mannava, Sindhu V , Fialkowski, Elizabeth A , Rich, Barrie S , Seemann, Natashia M , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Barkhordar, Aaron , Beckhorn, Catherine , Tracy, Elisabeth T , Malek, Marcus M , Kahan, Anastasia Morgan , Leraas, Harold J. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Murphy, Andrew J. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , López, Adriana , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn L. , Brown, Erin G. , Abril, Paige, Rinehardt, Hannah , Le, Hau D. , Ahmed, Tamer, Kim, Eugene S. , Pitonak, M.

Mayo Clinic

Pediatric Blood & Cancer | May 21, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31774 | PMID 40394815 Get It

ABSTRACTBackgroundRenal medullary carcinoma (RMC) is an aggressive tumor associated with sickle cell trait. Despite treatment advances for other rare renal tumors, RMC survival remains poor. We aimed to describe the contemporary management and survival of children and adults with RMC.ProcedureIn this multicenter retrospective cohort study, Pediatric Surgical Oncology Research Collaborative sites searched their databases for patients diagnosed with RMC (2000–2022). Descriptive statistics were calculated and survival analyses performed using Kaplan–Meier and Cox regression.ResultsThirty‐four patients with RMC were identified. Median age was 19 years (IQR: 15–28; range: 7–52). Most were male (24/34; 71%), Black (27/32; 84%), had sickle cell trait or disease (30/33; 91%), presented with metastatic disease (27/34; 79%), and were symptomatic at presentation (32/34; 94%). Median overall survival (OS) was 24 months from diagnosis (16 months for children, 28 months for adults, p = 0.6). Receipt of platinum‐based chemotherapy (23/34; 68%) was associated with significantly higher OS than other regimens (35 vs. 5 months, p < 0.001). Nephrectomy (24/34; 71%) was associated with significantly improved OS compared with non‐operative management (34 vs. 7 months, p = 0.001). Immunotherapy, targeted therapy, or radiation therapy were not associated with significant differences in OS, nor were age, sex, race, sickle cell status, SMARCB1/INI‐1, stage, nephrectomy approach, retroperitoneal lymph node dissection, gross residual disease, margins, or tumor size.ConclusionsRMC survival remains poor despite newer therapies. Nephrectomy and platinum‐based chemotherapy should be considered in locally advanced and metastatic disease. Coordinated international cooperative group studies are needed to meaningfully improve RMC survival.
Whole Genome Sequencing Analysis of Severe, Early-onset Chronic Obstructive Pulmonary Disease
Gharib, Salwa, Oelsner, E., Xu, Hanfei , Yu, Bing , Meyers, D.A., Norwood, Arnita F. , Ortega, V.E., Sliwiński, P, Medicine, Trans-Omics in Precision, Silverman, E.K., Cho, M.H. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Kim, Katherine Callaway , Hu, X., Chun, Sung , Rasmussen‐Torvik, Laura J. , Sofer, Tamar , Barr, R. Graham , Carson, April P. , Kalhan, Ravi , Kaplan, Robert C. , Lomas, David A. , London, Stephanie J. , Meyers, D.A., O’Connor, George T. , Psaty, Bruce M. , Rich, Stephen S. , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3380-A3380

10.1164/ajrccm.2025.211.abstracts.a3380 Get It

Abstract Background:Chronic obstructive pulmonary disease (COPD) is a major global health burden, with genome-wide association studies explaining only a fraction of its heritability. Recent advancements, including large-scale, multi-ancestry whole-genome sequencing and a focus on severe, early-onset cases, offer promising avenues to identify additional COPD-related variants. Furthermore, recent studies show that adjusting for polygenic risk scores (PRS) enhances statistical power to detect rare variants, advancing efforts to understand COPD's genetic basis. Methods:We performed a whole genome sequencing association study of severe, early-onset COPD (FEV1 &lt; 50%, age ≤ 55), FEV1 and FEV1/FVC in eight population-based studies (ARIC, CARDIA, CFS, CHS, FHS, HCHS/SOL, JHS, MESA) and seven COPD-enriched studies (COPDGene, ECLIPSE, Boston Early-Onset COPD Study, LTRC, TCGS (Poland), ICGN, SPIROMICS). We performed single-variant analyses using regenie software, applying a genome-wide significance threshold of P &lt; 5.0 x 10-8. For rare variant set (MAF &lt;1%) analysis, we annotated variants with loss of function or deleterious missense using WGS Annotator and prediction tools LOFTEE, SIFT, and PolyPhen2, then analyzed these variants with SKATO-ACAT method in regenie, adjusting for covariates including sex, sequencing center, and principal components of ancestry. We additionally evaluated adjusting the analyses for PRSs for lung function traits. Results: We analyzed 53,028 participants including 34,751 European, 12,508 African, 1,088 Latino American, and 674 East Asian ancestry. Across cohorts, we analyzed 5,063 severe (FEV1 &lt; 50%) COPD cases, among whom 1,103 were early-onset (age ≤ 55). Excluding variants within 1 Mbp of known variants, single-variant analysis identified 68 novel associations (MAC ≥ 30), with 8 common associations (MAF ≥ 1%) in 6 genomic regions. Our most significant novel association for severe early-onset COPD was rs74297390 (intergenic to POM121L12, MAF = 9.6%, Beta = 0.41, P = 3.5 x 10-8). For FEV1 and FEV1/FVC ratio, variants near DKK2 and AKR1E2 were significantly associated and were replicated in an independent dataset (Shrine et al., 2019). DKK2 is an antagonist in the Wnt pathway. In a preliminary variant set analysis, CHRM3-AS1 was associated with severe early-onset COPD, GPAT with FEV1, and COL8A1I and HMCN1 with FEV1/FVC. With PRS adjustment, ST6GALNAC5 was associated with FEV1/FVC. Conclusions: In a whole genome sequencing study of lung function and severe early-onset COPD, we identified new loci for COPD-related phenotypes, including two novel loci that replicated in an independent dataset. Ongoing work involves variant set-based analyses with additional covariate adjustments, as well as PRS adjustments for binary traits.
Leveraging Disease Relevant Transcriptomes From TOPMed LTRC Improves Polygenic Transcriptome Risk Prediction for COPD
Hu, Xin , Ardlie, Kristin , Lange, Leslie A., Lange, Ethan M. , Meyers, D.A., Bleecker, ER, Ortega, V.E., Silverman, Edward, Wheeler, Harry E., Liu, D., Cho, M.H., Barr, R. Graham , Kim, K., Wang, Li , Khunsriraksakul, Chachrit , Lappalainen, Tuuli , Aguet, François , Rich, Stephen S. , Rotter, Jerome I. , Meyers, D.A., Moll, Matthew , Castaldi, Peter J. , Hersh, Craig P. , Wheeler, H.E., Im, Hae Kyung , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2512-A2512

10.1164/ajrccm.2025.211.abstracts.a2512 Get It

Abstract RATIONALE: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality worldwide. We previously published the polygenic transcriptome risk score (PTRS) which uses the cumulative effect of predicted gene expression to construct genetic predictors for complex diseases, and we demonstrated the value of PTRS for COPD built on Genotype-Tissue Expression (GTEx) Lung tissue with significantly improved cross-ancestry portability. However, the postmortem collection and lack of lung disease status on GTEx samples likely affect results. We hypothesized that the performance of PTRS will be improved by using disease-relevant expression quantitative trait loci (eQTLs) to construct the score. Here, we aimed to improve performance of PTRS by leveraging disease-relevant eQTLs. METHODS: We constructed two transcriptome prediction models, Elastic Net (EN) and Prediction Using Models Informed by Chromatin conformation and Epigenomics (PUMICE), using TOPMed lung RNA-seq data from the Lung Tissue Research Consortium (LTRC), which included COPD patients undergoing lung surgery. We compared their performance with two published models built on RNA-seq from GTEx Lung tissue, GTEx-EN and GTEx-PUMICE. We first integrated each of four transcriptome models with multi-ancestry GWAS of FEV1/FVC ratio (Shrine et al. 2023) to generate transcriptome-wide association study (TWAS) results, which produced trait-associated genes. Pathway analysis was then conducted on significant TWAS genes. Finally, the PTRS was computed on TWAS genes that were included in the top 20 significantly enriched pathways. We tested performance of PTRS in race-stratified analysis for moderate-to-severe and severe COPD in COPDGene. RESULTS: Our models produced more significant TWAS genes (FDR&lt;0.05) and had more overlaps with genes identified for FEV1/FVC ratio from Shrine et al. 2023 compared to two GTEx models (Fig. A). Additionally, our models had significantly higher AUC for predicting both moderate-to-severe and severe COPD in race-stratified analysis. The mean AUC from LTRC-EN for predicting severe COPD was 0.57 and 0.55 respectively for EUR and AFA, which was significantly higher than mean AUC of 0.54 and 0.51 from GTEx-EN (Delong p-value=8.15x10-10 for EUR and 1.42x10-3 for AFA) (Fig. B). Similarly, the PTRS derived from our models produced higher Odds Ratios (OR) per standard deviation. The mean OR from LTRC-PUMICE for moderate-to-severe COPD was 1.25 and 1.18 respectively for EUR and AFA, while it was 1.17 and 1.12 from GTEx-PUMICE (Fig. C). CONCLUSIONS: Our study demonstrates the value of leveraging disease-relevant RNA-seq to construct transcriptome prediction models and their improvement on identifying lung function genes and predicting COPD across ancestries.
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation
Ng, Wee Han , Wang, Yun , Trivedi, Hirsh D. , Ayoub, Walid S. , Parikh, Neehar D. , Sheng‐Kai, Kevin , Yang, Ju Dong , Parikh, Neehar D , Ma, Kevin Sheng-Kai , Ahn, Joseph , Yeo, Yee Hui , Kim, Hyun-Seok, Kuo, Alexander , Rich, Nicole E. , Abou‐Alfa, Ghassan K. , Singal, Amit G., Yang, Ju Dong

Mayo Clinic

Hepatology | March 30, 2025 | Volume: 83 | Issue: 2 | Pages: 249-260

10.1097/hep.0000000000001328 | PMID 40153442 Get It

Background and Aims: Immunotherapy has emerged as an effective treatment for advanced HCC. We aimed to investigate the real-world effectiveness of immunotherapy compared to lenvatinib in HCC. Approach and Results: From the TriNetX database, we used a target trial emulation framework and identified patients with HCC who received first-line treatment with immunotherapy (atezolizumab/bevacizumab or tremelimumab/durvalumab) or lenvatinib between or between August 2018 and December 2023. OS was compared using Kaplan-Meier analysis and Cox proportional hazards regression. After propensity score matching, 1203 patients were included in each group. Immunotherapy was associated with improved OS versus lenvatinib (median survival: 545 vs. 425 d; HR: 0.86, 95% CI: 0.76–0.97). Regarding treatment type, atezolizumab plus bevacizumab showed improved survival compared to lenvatinib (n=1070 in each group; HR: 0.87, 95% CI: 0.77–0.99), while the point estimate favored durvalumab plus tremelimumab versus lenvatinib (HR: 0.81, 95% CI: 0.59–1.12), though this difference was not statistically significant, likely due to small sample size. Regarding etiology, immunotherapy had improved OS compared to lenvatinib in viral hepatitis (n=510 in each group; HR: 0.74, 95% CI: 0.61–0.89) and alcohol-associated liver disease (n=190 in each group; HR: 0.65, 95% CI: 0.49–0.87), but not in metabolic dysfunction–associated steatotic liver diseases (n=156 in each group; HR: 0.96, 95% CI: 0.70–1.31). Conclusions: In this real-world analysis, immunotherapy was associated with improved OS compared to lenvatinib in advanced HCC, with consistent benefit across most subgroups. These findings support the use of immunotherapy as a first-line treatment for advanced HCC.
Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.
Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Kick, Grace Robinson , Wang, Meifang , Snyder, Harper K., Moore, Peter J., Darvishi, Fereshteh B. , Dashtmian, Anna R. , Ayyagari, Sindhuja N. , Rich, Kelly , Arnold, W. David, Zhu, Yi , Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Ketabforoush, Arsh Haj Mohamad Ebrahim , Snyder, Harper K., Moore, Peter J., Zhu, Yi , Arnold, W. David

Mayo Clinic

No container title available | March 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6081213/v1 | PMID 40196013 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive motor neuron degeneration in the primary motor cortex (PMC) and spinal cord. Aging is a key factor in ALS onset and progression, with evidence suggesting that biological aging—a process involving cellular decline— far outpaces chronological aging in ALS. This promotes senescent cell accumulation—marked by irreversible cell-cycle arrest, impaired apoptosis, and chronic inflammation—disrupting tissue homeostasis and impairing neuronal support functions. Thus, targeting senescence presents a novel therapeutic strategy for ALS. Here, we investigated the senolytic combination Dasatinib and Quercetin (D&Q) in TDP-43 Q331K ALS mice. D&Q improved neuromuscular function and reduced plasma neurofilament light chain, a biomarker of axonal damage. The most pronounced improvement was the improved cortical excitability, accompanied by reductions in senescence and TDP-43 in the PMC. These findings highlight the potential of senolytics to mitigate ALS-related dysfunction, supporting their viability as a therapeutic strategy. *Jose A. Viteriab, Nathan R. Kerrab, and Charles D. Brennana are co-first authors.
Utility of Endoscopic Endonasal Cyst Fenestration and Marsupialization in the Treatment of Pediatric Craniopharyngioma
Rich, David, Venkatesh, Sanjena , Kohanski, Michael A. , Adappa, Nithin D. , Storm, Phillip B. , Lerner, David K. , Rich, Dominick, Workman, Alan D. , Barnett, Sarah, Eide, Jacob G. , Kundishora, Adam J. , Douglas, Jennifer E , Adappa, Nithin D.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803396 Get It

Platelet Concentration Explains Variability in Outcomes of Platelet-Rich Plasma for Lateral Epicondylitis: A High Dose Is Critical for a Positive Response: A Systematic Review and Meta-analysis With Meta-regression
Oeding, Jacob F. , Varady, Nathan H. , Messer, Caden J., Williams, Riley J. , Rodeo, Scott A. , Williams, Riley J , Rodeo, Scott A , Oeding, Jacob F , Dines, Joshua S.

Mayo Clinic

The American Journal of Sports Medicine | January 29, 2025 | Volume: 53 | Issue: 10 | Pages: 2489-2496

10.1177/03635465241303716 | PMID 39868742 Get It

Background: Randomized controlled trials (RCTs) evaluating the efficacy of platelet-rich plasma (PRP) for the management of lateral epicondylitis (LE) have been characterized by substantial variability in reported outcomes. The source of this heterogeneity is uncertain. Purpose: To determine the effect of estimated platelet concentration on the efficacy of PRP for the management of LE. Study Design: Systematic review and meta-analysis; Level of evidence, 2. Methods: All RCTs evaluating the efficacy of PRP in managing LE were identified. RCTs were classified according to whether the study documented a platelet concentration factor of PRP representing a greater than 3-fold increase over whole blood or a supraphysiological platelet dose (high-dose vs low-dose PRP). The primary outcome was the mean difference (MD) in the visual analog scale (VAS) score at latest follow-up. Random-effects and mixed-effects meta-analyses were performed, and meta-regression was used to evaluate whether differences in outcomes after treatment with PRP could be explained by differences in the concentration of PRP used. Results: Overall, 13 RCTs with a total of 791 patients were included in this analysis, with 5 that utilized low-dose PRP and 8 that used high-dose PRP. Meta-analysis of VAS scores reported by studies that used high-dose PRP resulted in an MD of −1.31 (95% CI, −1.87 to −0.75) in favor of PRP over all alternative treatment strategies ( P < .001). Meta-analysis of VAS scores reported by studies that used low-dose PRP resulted in an MD of 0.08 (95% CI, −0.51 to 0.68), suggesting no difference in the effect between PRP and all alternative treatment strategies ( P = .79). The platelet concentration factor of PRP used in each RCT was found to be strongly predictive of the VAS score at final follow-up in meta-regression ( P < .001), with 58.5% of the heterogeneity in the outcomes of PRP between studies explained by the platelet concentration factor alone. Conclusion: The platelet concentration of PRP may play a significant role in the outcomes of patients with LE. A direct linear relationship was observed between the platelet concentration factor of PRP used and the magnitude of patient-reported symptom relief after the management of LE with PRP. Clinicians should ensure a supraphysiological platelet concentration when preparing PRP for the management of LE.
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad, Amini, Arya , Bibee, Kristin , Bolotin, Diana, DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , LeBoeuf, Nicole R. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Paragh, György , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Sharma, Bhavina, Sokumbi, Yemi, Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Bordeaux, Jeremy S. , Chen, Pei-Ling , Contreras, Carlo M. , Donigan, Jessica M. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Sharma, Bhavina, Srivastava, Divya , Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2025.0001 | PMID 39819674 Get It

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.
Optimizing Antibiotic Management for Adult Patients Presenting with Acute Perforated Appendicitis: A Quality Improvement Study
Gallego-Navarro, Carlos , Linnaus, Maria E., Swartz, Hayden J., Stewart, Shelby , York, Justin, Gassner, Ryan R , Kasal, Christopher A. , Seidel, Annaliese G., Wachter, Corey J., Kooda, Kirstin , Rich, Jennifer R. , Sawyer, Mark D. , Beckermann, Jason , York, Justin M, Kooda, Kirstin J

Mayo Clinic

Surgical Infections | November 12, 2024 | Volume: 26 | Issue: 3 | Pages: 143-149

10.1089/sur.2024.179 | PMID 40179309 Get It